Equities Research Analysts’ Updated EPS Estimates for June 12th (ADBE, BANF, BNL, CLYM, COYA, DIS, DMRA, DRVN, EPR, ES)

Equities Research Analysts’ updated eps estimates for Friday, June 12th:

Adobe (NASDAQ:ADBE) had its market perform rating reiterated by analysts at Citizens Jmp.

BancFirst (NASDAQ:BANF) had its neutral rating reissued by analysts at DA Davidson. DA Davidson currently has a $125.00 target price on the stock.

Broadstone Net Lease (NYSE:BNL) was downgraded by analysts at Citizens Jmp from an outperform rating to a market perform rating.

Climb Bio (NASDAQ:CLYM) had its outperform rating reissued by analysts at Wedbush. They currently have a $17.00 target price on the stock.

Coya Therapeutics (NASDAQ:COYA) had its buy rating reissued by analysts at Chardan Capital. They currently have a $14.00 target price on the stock.

Walt Disney (NYSE:DIS) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $125.00 target price on the stock.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) had its outperform rating reiterated by analysts at Wedbush. They currently have a $35.00 price target on the stock.

Driven Brands (NASDAQ:DRVN) had its buy rating reaffirmed by analysts at BTIG Research. They currently have a $17.00 price target on the stock.

EPR Properties (NYSE:EPR) was upgraded by analysts at Citizens Jmp from a market perform rating to an outperform rating. They currently have $70.00 price target on the stock.

Eversource Energy (NYSE:ES) was downgraded by analysts at Argus from a buy rating to a hold rating.

First American Financial (NYSE:FAF) had its overweight rating reaffirmed by analysts at Stephens. The firm currently has a $84.00 target price on the stock.

fuboTV (NYSE:FUBO) had its buy rating reaffirmed by analysts at Needham & Company LLC. They currently have a $15.00 price target on the stock.

IDEAYA Biosciences (NASDAQ:IDYA) had its outperform rating reissued by analysts at Wedbush. The firm currently has a $58.00 target price on the stock.

Immunome (NASDAQ:IMNM) had its outperform rating reiterated by analysts at Wedbush. The firm currently has a $31.00 target price on the stock.

Kratos Defense & Security Solutions (NASDAQ:KTOS) was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. JPMorgan Chase & Co. currently has $82.00 target price on the stock, down from their previous target price of $99.00.

MarketAxess (NASDAQ:MKTX) was upgraded by analysts at Bank of America Corporation from an underperform rating to a neutral rating. Bank of America Corporation currently has $170.00 target price on the stock.

Marvell Technology (NASDAQ:MRVL) had its buy rating reissued by analysts at Rosenblatt Securities. Rosenblatt Securities currently has a $240.00 price target on the stock.

Hyperliquid Strategies (NASDAQ:PURR) had its buy rating reissued by analysts at Chardan Capital. Chardan Capital currently has a $9.75 target price on the stock.

RH (NYSE:RH) had its buy rating reaffirmed by analysts at Guggenheim. They currently have a $200.00 price target on the stock.

Rolls-Royce Holdings PLC (OTCMKTS:RYCEY) was upgraded by analysts at Berenberg Bank from a hold rating to a buy rating.

SailPoint (NASDAQ:SAIL) had its neutral rating reaffirmed by analysts at Bank of America Corporation. They currently have a $16.00 target price on the stock.

Syndax Pharmaceuticals (NASDAQ:SNDX) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $40.00 target price on the stock.

Triple Flag Precious Metals (NYSE:TFPM) was upgraded by analysts at Canaccord Genuity Group Inc. from a hold rating to a buy rating.

Tesla (NASDAQ:TSLA) had its sell rating reiterated by analysts at Glj Research.

Titan International (NYSE:TWI) had its buy rating reaffirmed by analysts at DA Davidson. They currently have a $13.00 price target on the stock.

Upstream Bio (NASDAQ:UPB) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating. The firm currently has $8.00 price target on the stock, down from their previous price target of $35.00.

Zscaler (NASDAQ:ZS) had its overweight rating reiterated by analysts at Stephens. The firm currently has a $200.00 price target on the stock.